Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y
Signal Transduct Target Ther. 2024; 9(1):132.
PMID: 38763973
PMC: 11102923.
DOI: 10.1038/s41392-024-01823-2.
Zhao J, Zeng Z
Medicine (Baltimore). 2020; 99(26):e20400.
PMID: 32590727
PMC: 7328912.
DOI: 10.1097/MD.0000000000020400.
Liu J, Zheng Y, Gao Y, Quan Z, Qiao B, Li L
Front Oncol. 2020; 10:75.
PMID: 32158687
PMC: 7051985.
DOI: 10.3389/fonc.2020.00075.
Gonzalez-Sanchez E, Martin-Caballero J, Maria Flores J, Hernandez-Losa J, Cortes J, Mares R
PLoS One. 2013; 8(6):e66933.
PMID: 23825589
PMC: 3692542.
DOI: 10.1371/journal.pone.0066933.
Hafner C, Groesser L
Cell Cycle. 2012; 12(1):43-50.
PMID: 23255105
PMC: 3570515.
DOI: 10.4161/cc.23108.
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
Li T, Guo M, Gradishar W, Sparano J, Perez E, Wang M
Breast Cancer Res Treat. 2012; 134(1):345-52.
PMID: 22547107
PMC: 4596817.
DOI: 10.1007/s10549-012-2071-z.
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Derer S, Berger S, Schlaeth M, Schneider-Merck T, Klausz K, Lohse S
Neoplasia. 2012; 14(3):190-205.
PMID: 22496619
PMC: 3323897.
DOI: 10.1593/neo.111636.
Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.
Kratz C, Rapisuwon S, Reed H, Hasle H, Rosenberg P
Am J Med Genet C Semin Med Genet. 2011; 157C(2):83-9.
PMID: 21500339
PMC: 3086183.
DOI: 10.1002/ajmg.c.30300.
The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
Nevo Y, Aga-Mizrachi S, Elmakayes E, Yanay N, Ettinger K, Elbaz M
PLoS One. 2011; 6(3):e18049.
PMID: 21445359
PMC: 3062565.
DOI: 10.1371/journal.pone.0018049.
Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling.
Mukhopadhyay A, Krishnaswami S, Yu B
J Invest Dermatol. 2010; 131(2):311-9.
PMID: 20944652
PMC: 3335744.
DOI: 10.1038/jid.2010.296.
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M
Cancer Sci. 2010; 101(5):1080-8.
PMID: 20331636
PMC: 11158590.
DOI: 10.1111/j.1349-7006.2010.01505.x.
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.
Peipp M, Dechant M, Valerius T
MAbs. 2010; 1(6):590-9.
PMID: 20068398
PMC: 2791317.
DOI: 10.4161/mabs.1.6.10051.
Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes.
Balestrieri C, Alberghina L, Vanoni M, Chiaradonna F
BMC Bioinformatics. 2009; 10 Suppl 12:S1.
PMID: 19828069
PMC: 2762058.
DOI: 10.1186/1471-2105-10-S12-S1.
Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome.
Hu H, Qin Y, Bochorishvili G, Zhu Y, Van Aelst L, Zhu J
J Neurosci. 2008; 28(31):7847-62.
PMID: 18667617
PMC: 2553221.
DOI: 10.1523/JNEUROSCI.1496-08.2008.
H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors.
Serban D, Leng J, Cheresh D
Circ Res. 2008; 102(11):1350-8.
PMID: 18467631
PMC: 2743877.
DOI: 10.1161/CIRCRESAHA.107.169664.
A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.
Jasinski P, Welsh B, Galvez J, Land D, Zwolak P, Ghandi L
Invest New Drugs. 2007; 26(3):223-32.
PMID: 17957339
DOI: 10.1007/s10637-007-9096-x.
